- Home
- TRIB vs APLM Comparison
TRIB vs APLM Comparison
Compare TRIB & APLM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TRIB
- APLM
- Stock Information
- Founded
- TRIB 1992
- APLM 2016
- Country
- TRIB Ireland
- APLM United States
- Employees
- TRIB N/A
- APLM N/A
- Industry
- TRIB Biotechnology: In Vitro & In Vivo Diagnostic Substances
- APLM Blank Checks
- Sector
- TRIB Health Care
- APLM Finance
- Exchange
- TRIB Nasdaq
- APLM Nasdaq
- Market Cap
- TRIB 5.4M
- APLM 6.1M
- IPO Year
- TRIB N/A
- APLM N/A
- Fundamental
- Price
- TRIB $1.11
- APLM $5.43
- Analyst Decision
- TRIB
- APLM
- Analyst Count
- TRIB 0
- APLM 0
- Target Price
- TRIB N/A
- APLM N/A
- AVG Volume (30 Days)
- TRIB 13.5M
- APLM 37.4K
- Earning Date
- TRIB 11-14-2025
- APLM 09-19-2025
- Dividend Yield
- TRIB N/A
- APLM N/A
- EPS Growth
- TRIB N/A
- APLM N/A
- EPS
- TRIB N/A
- APLM N/A
- Revenue
- TRIB $61,555,000.00
- APLM $198,000.00
- Revenue This Year
- TRIB $13.51
- APLM $415.15
- Revenue Next Year
- TRIB $13.14
- APLM N/A
- P/E Ratio
- TRIB N/A
- APLM N/A
- Revenue Growth
- TRIB 8.31
- APLM N/A
- 52 Week Low
- TRIB $0.48
- APLM $3.66
- 52 Week High
- TRIB $3.44
- APLM $35.98
- Technical
- Relative Strength Index (RSI)
- TRIB 45.04
- APLM 49.66
- Support Level
- TRIB $1.42
- APLM $3.66
- Resistance Level
- TRIB $1.58
- APLM $6.37
- Average True Range (ATR)
- TRIB 0.15
- APLM 0.59
- MACD
- TRIB -0.07
- APLM -0.01
- Stochastic Oscillator
- TRIB 2.80
- APLM 65.22
About TRIB Trinity Biotech plc
Trinity Biotech PLC is in the business of developing, manufacturing, and marketing clinical diagnostic products for clinical laboratory and point-of-care sections of the diagnostic market. Its products are used to detect autoimmune, infectious, sexually transmitted diseases, diabetes, and disorders of the liver and intestine. The company also provides raw materials to the life sciences and research industries globally. It markets products under the brand names Recombigen, Unigold, MarBlot, Mardx, Immublot, and others. Geographically, it has two segments namely the Americas, and the Rest of World - Ireland from which it derives a majority of its revenue from the Americas segment.
About APLM Apollomics Inc.
Apollomics Inc is an clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company programs include vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia.